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Objectives: Toxic death is a big problem in the treatment of childhood acute lymphoblastic 
leukemia (ALL), especially in low-income countries. Studies of ciprofloxacin as single agent 
prophylaxis vary widely in success rate. We conducted a double-blind, randomized study to 
test the effects of ciprofloxacin monotherapy as prophylaxis for sepsis and death in induction 
treatment of the Indonesian childhood ALL protocol.
Methods: Patients were randomized to the ciprofloxacin arm (n = 58) and to the placebo 
arm (n = 52). Oral ciprofloxacin monotherapy or oral placebo was administered twice a day. 
All events during induction were recorded: toxic death, abandonment, resistant disease, and 
complete remission rate.
Results: Of 110 patients enrolled in this study, 79 (71.8%) achieved CR. In comparison to the 
placebo arm, the ciprofloxacin arm had lower nadir of absolute neutrophil count during induc-
tion with median of 62 (range: 5–884) versus 270 (range: 14–25,480) × 109 cells/L (P , 0.01), 
greater risks for experiencing fever (50.0% versus 32.7%, P = 0.07), clinical sepsis (50.0% 
versus 38.5%, P = 0.22), and death (18.9% versus 5.8%, P = 0.05).
Conclusion: In our setting, a reduced intensity protocol in a low-income situation, the data 
warn against using ciprofloxacin prophylaxis during induction treatment. A lower nadir of 
neutrophil count and higher mortality were found in the ciprofloxacin group.
Keywords: ciprofloxacin, prophylaxis, childhood acute lymphoblastic leukemia, randomized 
trial, low-income country
Introduction
Childhood acute lymphoblastic leukemia (ALL) patients may experience 
  immunosuppression, either due to the disease or as a result of chemotherapy, or both. 
This condition occurs particularly during induction and re-induction phases, in which 
intensive treatment is conducted.1–3 It may lead to fatal infections, especially if the 
patients are malnourished and if there is lack of access to supportive care. Previous 
studies have shown that prophylactic antimicrobial treatment can reduce infection-
related morbidity and mortality after oral or intravenous administration.4–9
Contrary to the setting in high-income countries, poverty, malnutrition, and the 
generally poor clinical condition of patients, as well as poor access to supportive care 
in low- to middle-income countries, have generated a higher incidence of treatment-
related mortality and lower remission rates. A study in Dr Sardjito Hospital, Yogyakarta, 
Indonesia, as reported by Mostert et al,10 revealed that between 1997 and 2002 the 
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toxic death rate was an obvious problem; approximately 
23% of patients experienced treatment-related death and 
35% refused or abandoned treatment. The majority of these 
events occurred during induction. Both events result in low 
remission and cure rates in our hospital setting.
We therefore conducted this randomized, double-blind 
study to test the role of ciprofloxacin oral monotherapy 
as prophylaxis for bacterial infection and toxic death dur-
ing induction treatment of Indonesian childhood ALL 
protocol.
Patients and methods
Patients
The study groups consisted of children with ALL hospitalized 
in Dr Sardjito Hospital, Yogyakarta, Indonesia from July 1999 
until June 2005, who met the inclusion criteria as   follows: 
diagnosis of ALL based on French–American–British mor-
phology classification of L1 or L2;11 and age between 0 and 
14 completed years during induction treatment for the stan-
dard risk (SR) and high risk (HR) groups of the   Indonesian 
Wijaya Kusuma (WK)-ALL-2000 protocol. Patients were 
defined as SR when their age at diagnosis was between 
1 year and 9 completed years; their WBC count was less than 
50 × 109/L; and there was an absence of mediastinal mass 
and no signs of central nervous system (CNS) involvement. 
Patients who did not meet SR criteria were assigned as HR. 
SR patients with a day 8 absolute peripheral lymphoblasts 
count 1 × 109/L or higher were upgraded to the HR group 
and treated accordingly. Fever was defined as an axillary 
temperature $ 38.5°C in a single determination or .38°C 
after two measurements with a 1-hour interval between 
each measurement. Clinical sepsis was defined when there 
was fever plus documented clinical signs and symptoms of 
systemic infection with or without increasing C-reactive 
protein level. Microbiological studies and surveillance were 
not always done for financial reasons.
The exclusion criteria were known allergy to quinolo-
nes, epilepsy, and/or body weight (BW) less than 10 kg. 
Patients were classified as undernourished at diagnosis when 
Z-score value was -2 SD or less based on weight-for-age 
(0–5 years) and height-for-age (5–15 years) World Health 
Organization standards for nutritional status.12,13
The WK-ALL-2000 protocol
The WK-ALL-2000 protocol for childhood ALL was devel-
oped in 1998–1999 as a relatively economical, reduced-
intensity protocol to meet conditions in Indonesia after the 
Asian economical crisis.14 The protocol includes a 6-week 
induction treatment of three doses of weekly age-adjusted 
intrathecal methotrexate administered in weeks 0, 2, and 6; 
daily oral dexamethasone 6 mg/m2 for 42 days; five doses of 
weekly intravenous vincristine 1.5 mg/m2 during weeks 1–5; 
and two doses of intravenous Escherichia coli L-asparaginase 
6000 IU/m2 in weeks 1 and 2 for SR or weeks 4 and 5 for HR 
patients. One dose of intravenous daunorubicin 30 mg/m2 
was added at week 1 for HR patients only. HR patients also 
received a re-induction schedule inserted between the con-
solidation and maintenance phase. The scheme of the protocol 
is shown in Table 1.
random assignment
Patients were randomized using a computer into arm A and 
arm B. Arm A had tablets containing ciprofloxacin prepared 
in the pharmacy, while the placebo tablet contained tasteless 
material. Both the patients and the doctors and other staff 
were blinded to the tablet contents, and the groups were not 
unblinded until after the inclusion period had ended.
The tablets were taken orally twice per day from the onset 
of chemotherapy administration. The ciprofloxacin doses 
depended on the patient’s BW: BW 10–14 kg = 2 × 125 mg; 
BW 15–24 kg = 2 × 250 mg; BW 25–39 kg = 2 × 500 mg; 
and BW 40 kg or more = 2 × 750 mg. The tablets were taken 
continuously at home when the patient was discharged from 
hospital until completion of induction treatment. Modification 
of this treatment was permitted if the patient had fever.
Statistical analysis
The data were collected in a research-patient file and trans-
ferred to a computer spreadsheet form containing informa-
tion of the protocol used, presentation at diagnosis (sex, age 
group, WBC group, risk group, nutritional status), day 8 
peripheral lymphoblasts count, any fever and clinical sepsis, 
date of death or abandonment, and remission status at the 
end of the induction treatment.
The protocol stated day 43 as the end of induction 
treatment and remission determination. Patients achieved 
complete remission when their lymphoblast count in bone 
marrow was less than 5% without any signs of leukemic 
infiltration in peripheral blood, cerebrospinal fluid, or other 
organs. Abandonment of treatment, death, and no remission 
achievement were classified as induction failures.
The outcomes measured in this study were fever, clini-
cal sepsis and mortality. The analysis was carried out using 
SPSS software (v13; IBM Corporation, Armonk, NY) 
and   statistical significance was defined at the two-sided 
P-value , 0.05.
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Results
One-hundred and ten patients were enrolled in this study 
and randomized into arm A (58 patients or 53%) and arm B 
(52 patients or 47%). The characteristics of patients were not 
equally divided between the two groups as shown in Table 2. 
The ciprofloxacin group was less often under-nourished 
than the placebo group (24.1% vs 44.2%, P = 0.03).
Of the 110 patients, 79 (71.8%) achieved complete 
  remission. Adverse outcomes during induction treatment 
were dominated by death (12.8%) and abandonment (9.0%). 
The remaining patients (6.4%) had resistant disease. Patients 
in the ciprofloxacin arm have a greater induction failure rate 
(31.0% vs 25.0%; 95% CI: 0.58–3.12; P = 0.48; Table 3), 
more fever (50.0% vs 32.7%; 95% CI: 0.95–4.47; P = 0.07), 
more clinical sepsis (50.0% vs 38.5%; 95% CI: 0.75–3.42; 
P = 0.22), and more toxic death (18.9% vs 5.8%; 95% CI: 
0.92–13.80; P = 0.05). However, these results were not sta-
tistically significant. Twelve of 14 induction deaths occurred 
in the hospital; six of these were infective death, due to sepsis 
(five patients) and varicella (one patient) as shown in Table 4. 
However, the patients diagnosed with disseminated intravas-
cular coagulation, multiorgan   dysfunction syndrome, and 
shock may well have had infection as the causative event. 
The nadir of the absolute neutrophil count during induction 
in the ciprofloxacin arm was lower than in the placebo arm 
(median 62 [range: 5–884] vs 270 [range: 14–25,480] cells/
µl; P , 0.01). The ciprofloxacin arm and the placebo arm 
had an equal induction duration (median 43 [range: 40–58] 
vs 43 [range: 39–59] days, respectively).
Table 5 shows that there was no significant difference in the 
incidence of diarrhea, nausea, vomiting, and neuritis as adverse 
events during induction between the ciprofloxacin arm and 
placebo arm. The characteristics and clinical outcome during 
induction treatment of each patient is shown in Table 6.
Discussion
Deaths, whether related to the disease itself or chemotherapy-
induced, are common in leukemia treatment. The toxic death 
rate (23%) together with treatment refusal or abandonment of 
treatment (35%) are big problems in Dr Sardjito Hospital.10 
Table 2 Characteristics of patients
Characteristics Placebo Ciprofloxacin Total P-value
n % n % n %
Total patients 52 47.3 58 52.7 110 100
Sex
  Male 34 65.4 37 60.3 69 62.7 0.86
  Female 18 34.6 21 39.7 41 37.3
Age group (years)
  1–9 40 76.9 49 84.5 89 80.9 0.31
  10–14 12 23.1 9 15.5 21 19.1
WBC at diagnosis (×109/L)
  ,50 37 71.2 43 74.1 80 72.7 0.73
  $50 15 28.8 15 25.9 30 27.3
risk group
  Standard risk 27 51.9 32 55.2 59 53.6 0.73
  High risk 25 48.1 26 44.8 51 46.4
Nutritional status
  Well-nourished 29 55.8 44 75.9 73 66.4 0.03
  Undernourished 23 44.2 14 24.1 37 33.6
Day 8 absolute peripheral  
lymphoblasts count (×109/L)a
  ,1 40 80.0 44 80.0 84 80.0 1.00
  $1 10 20.0 11 20.0 21 20.0
Note: aData were not available in five patients due to death or abandonment of treatment before measurement (n = 3 in ciprofloxacin group, n = 2 in placebo group).
Abbreviation: WBC, white blood cell.
Table 1 Induction treatment of WK-ALL-2000 protocol.14
Medicine Schedule of administration
Methotrexate, ith Days 1, 15, 42
Dexamethasone 6 mg/m2, po Days 1–42
Vincristine 1.5 mg/m2, iv Days 8, 15, 22, 29, 36
L-asparaginase 6.000 U/m2, iv Days 8, 15 (standard-risk 
patients) or Days 29, 36  
(high-risk patients)
Daunorubicin 30 mg/m2, iv Day 8 (high-risk patients only)
Notes: The dose of ith methotrexate was adjusted to age: ,1 year = 6 mg; 1–2 
years = 8 mg; 2–3 years = 10 mg; $ 3 years = 12 mg. The dose of oral dexamethasone 
was tapered-on during the first week when the initial WBC count was .20 × 109/L 
and tapered-off during the sixth week in all patients. Bone marrow aspirations were 
done on day 0 for diagnosis and at the end of induction treatment to determine 
remission achievement.
Abbreviations: ith, intrathecal; po, per oral; iv, intravenous; WK-ALL-2000, Wijaya 
Kusuma acute lymphoblastic leukemia protocol.
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These kinds of problems are typically found in resource-poor 
countries with poor and malnourished patients, poor access 
to supportive care, and lack of access to medicines.15–17 
The condition is contrary to that in high-income countries 
where toxic death rates are generally much fewer (2%–4%) 
and abandonment is virtually unknown.18,19 An important 
underlying cause of a high toxic death rate in childhood ALL 
is neutropenia, which may be found at diagnosis as a con-
sequence of the leukemia itself, or following chemotherapy. 
Infections in individuals with neutropenia can develop into 
a life threatening condition and therefore require prompt 
intervention. Initiation of empiric antibiotics immediately 
after the neutropenic cancer patient becomes febrile has been 
the single most important advance in the management efforts 
to diminish mortality rates in the immunocompromized 
host.20 Unfortunately, trials to decrease the infection-related 
mortality in neutropenic patients utilizing antibacterial pro-
phylaxis and the use of hematopoietic growth-stimulating 
factors have shown conflicting results.8,21–24 In terms of 
primary antibiotic prophylaxis, ciprofloxacin or quinolone 
derivates have been widely used because they show wide 
  antibacterial spectrum activity, mainly against Gram-negative 
bacteria from the gut, where invasive bacteria for systemic 
infection originate. Another benefit of quinolones, besides 
their effectiveness, is that they are generally well-tolerated 
and can be administered orally.7,25,26 Based on such findings, 
and because it is available at low-cost in our setting, we used 
ciprofloxacin in our study. We hypothesized that prophylactic 
ciprofloxacin administration would diminish infection and 
mortality during induction, thus increasing the remission and 
cure rates of childhood ALL in our hospital setting.
Some unexpected results were obtained in our study. First 
of all, the randomization was not balanced for malnutrition, 
and the ciprofloxacin group had the lower percentage of mal-
nourished patients. It is clear that malnutrition is an important 
factor for fever and infection; nevertheless, patients in the 
ciprofloxacin arm showed a higher risk of developing fever, 
clinical sepsis, and death from complications than patients in 
the placebo arm. Therefore, we checked whether the groups 
had not been accidentally exchanged, but this was not the 
Table 3 Outcomes during induction treatment
Outcomes Placebo Ciprofloxacin Total OR 95% CI P-value
n % n % n %
Total patients 52 47.3 58 52.7 110 100
Induction outcome
  Complete remission 39 75.0 40 69.0 79 71.8
  Induction failures 13 25.0 18 31.0 31 28.2 1.35a 0.58–3.12 0.48#
    Death 3 5.8 11 18.9 14 12.8 3.57a 0.92–13.80 0.05#
    Abandonment 7 13.5 3 5.2 10 9.0 0.42a 0.10–1.73 0.32##
    resistant disease 3 5.8 4 6.9 7 6.4 1.3a 0.27–6.19 1.00##
Fever . 38.5°C
  Never 35 67.3 29 50.0 64 58.2
  Ever 17 32.7 29 50.0 46 41.8 2.06b 0.95–4.47 0.07#
Clinical sepsis
  Never 32 61.5 29 50.0 61 55.5
  Ever 20 38.5 29 50.0 49 44.5 1.60b 0.75–3.42 0.22#
Notes: aORs for any induction failure and specific induction failures (CR is taken as the reference outcome category); bOrs for event of fever and clinical sepsis (Never is 
taken as the reference outcome category); #Chi-square test; ##Fisher’s exact test.
Abbreviations: OR, odds ratio (ciprofloxacin group relative to placebo group); CI, confidence interval.
Table 5 Adverse events during induction treatment
Events Placebo Ciprofloxacin Total
n % n % n %
Total patients 52 47.3 58 52.7 110 100
Nausea 8 15.4 3 5.2 11 10.0
Vomiting 7 13.5 6 10.3 13 11.8
Diarrhea 2 3.8 4 6.9 6 5.5
Neuritis 7 13.5 5 8.6 12 11.0
Table 4 Cause of death during induction treatment
Causes of death Placebo Ciprofloxacin Total
n % n % n %
Total patients 3 11.4 11 78.6 14 100
Sepsis 3 5.8 2 3.4 5 35.7
Varicella 0 0 1 1.7 1 7.1
Intracranial hemorrhage 0 0 2 3.4 2 14.2
DIC 0 0 1 1.7 1 7.1
MODS 0 0 1 1.7 1 7.1
Hypovolemic shock 0 0 1 1.7 1 7.1
Transfusion reaction 0 0 1 1.7 1 7.1
No data or died at home 0 0 2 3.4 2 14.2
Abbreviations:  DIC,  disseminated  intravascular  coagulation;  MODS,  multiple 
organ dysfunction syndrome.
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Table 6 Presentation at diagnosis and clinical outcome
Patient Random Sex Age 
(years,  
months)
WBC  
count  
(/μl)
Risk  
group
Nutritional 
state
Day 8  
response 
(/μl)
Induction  
outcome
Cause  
of death
Fever Sepsis
1 Cip M 7, 02 ,50,000 Sr Well ,1000 Cr Ever Never
2 Pcb F 5, 05 $50,000 Hr Well ,1000 Cr Never Never
3 Pcb F 5, 01 ,50,000 Sr Well $1000 Cr Never Never
4 Cip F 3, 04 ,50,000 Sr Well ,1000 Cr Ever Ever
5 Cip M 10, 00 $50,000 Hr Well ,1000 Cr Never Never
6 Cip F 10, 00 $50,000 Hr Under ,1000 rD Ever Never
7 Pcb M 1, 00 $50,000 Hr Under $1000 Cr Ever Ever
8 Cip M 4, 01 $50,000 Hr Well $1000 Death Disseminated  
intravascular  
coagulation
Ever Never
9 Pcb M 14, 01 $50,000 Hr Under $1000 Death Sepsis Ever Ever
10 Cip M 4, 04 $50,000 Hr Well ,1000 Death Sepsis Ever Ever
11 Pcb M 7, 03 $50,000 Hr Under ,1000 Death Sepsis Never Never
12 Cip F 5, 11 $50,000 Hr Well $1000 Cr Ever Ever
13 Cip M 2, 07 ,50,000 Sr Under ,1000 Cr Ever Ever
14 Cip F 14, 01 $50,000 Hr Well $1000 Cr Ever Never
15 Cip M 8, 06 ,50,000 Sr Under ,1000 Cr Ever Ever
16 Cip F 1, 08 ,50,000 Sr Well ,1000 Cr Never Ever
17 Pcb M 2, 06 ,50,000 Sr Well ,1000 Cr Ever Ever
18 Pcb M 13, 00 ,50,000 Hr Under ,1000 Cr Never Ever
19 Cip M 1, 10 ,50,000 Hr Well ,1000 Cr Never Ever
20 Pcb M 2, 05 $50,000 Hr Well ,1000 Cr Never Never
21 Pcb M 13, 01 ,50,000 Hr Well ,1000 Cr Never Never
22 Pcb F 9, 09 ,50,000 Sr Well ,1000 Cr Ever Never
23 Pcb F 6, 06 ,50,000 Sr Well ,1000 Cr Ever Ever
24 Cip F 6, 07 ,50,000 Sr Under ,1000 Cr Never Never
25 Cip M 2, 09 ,50,000 Sr Well ,1000 Cr Never Never
26 Pcb M 8, 01 ,50,000 Sr Well ,1000 Cr Never Never
27 Cip M 7, 05 ,50,000 Sr Well ,1000 Cr Never Ever
28 Cip M 1, 08 $50,000 Hr Well ,1000 Cr Ever Ever
29 Pcb M 6, 03 ,50,000 Sr Under ,1000 Cr Never Never
30 Cip M 13, 00 $50,000 Hr Well $1000 rD Ever Ever
31 Pcb M 2, 01 ,50,000 Sr Under ,1000 Cr Ever Ever
32 Pcb F 14, 00 $50,000 Hr Under $1000 rD Never Never
33 Cip F 1, 06 ,50,000 Sr Well ,1000 Cr Never Ever
34 Pcb M 6, 06 ,50,000 Sr Well ,1000 Cr Never Ever
35 Cip M 3, 03 ,50,000 Sr Under ,1000 Cr Ever Ever
36 Pcb F 7, 08 ,50,000 Sr Well ,1000 Cr Never Never
37 Pcb M 3, 03 ,50,000 Sr Under ,1000 Abn Never Ever
38 Pcb F 2, 11 ,50,000 Sr Well ,1000 Cr Never Never
39 Cip M 5, 01 ,50,000 Sr Well ,1000 Cr Ever Never
40 Cip M 3, 02 $50,000 Hr Well ,1000 Cr Ever Never
41 Pcb M 4, 03 ,50,000 Sr Well ,1000 Cr Ever Ever
42 Pcb M 6, 07 ,50,000 Sr Well ,1000 Cr Never Never
43 Cip F 4, 00 ,50,000 Sr Under ,1000 Cr Ever Ever
44 Cip M 14, 00 $50,000 Hr Under $1000 Abn Never Ever
45 Pcb M 4, 01 ,50,000 Sr Well ,1000 Cr Never Never
46 Pcb M 1, 03 ,50,000 Sr Well ,1000 Abn Ever Ever
47 Pcb F 7, 07 ,50,000 Sr Well ,1000 Abn Never Never
48 Pcb M 12, 01 ,50,000 Hr Under No data Abn Never Never
49 Pcb M 4, 02 ,50,000 Sr Under ,1000 Cr Ever Ever
50 Cip F 6, 05 ,50,000 Hr Well ,1000 Cr Ever Ever
(Continued)
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Table 6 (Continued)
Patient Random Sex Age 
(years,  
months)
WBC  
count  
(/μl)
Risk  
group
Nutritional 
state
Day 8  
response 
(/μl)
Induction  
outcome
Cause  
of death
Fever Sepsis
51 Cip M 3, 04 ,50,000 Hr Well ,1000 Cr Never Never
52 Cip F 11, 00 ,50,000 Hr Under ,1000 Death Sepsis Ever Ever
53 Pcb M 4, 08 $50,000 Hr Well No data Death Sepsis Ever Ever
54 Cip M 2, 05 ,50,000 Hr Under No data Death Multiple  
organs  
dysfunction
Ever Ever
55 Pcb M 5, 02 ,50,000 Sr Under ,1000 Cr Ever Never
56 Cip F 8, 01 ,50,000 Sr Well ,1000 Cr Never Never
57 Cip M 2, 08 ,50,000 Sr Well ,1000 Cr Ever Never
58 Cip M 4, 09 ,50,000 Hr Well ,1000 Cr Ever Ever
59 Cip M 9, 03 ,50,000 Sr Under ,1000 rD Ever Never
60 Cip F 9, 07 ,50,000 Sr Well ,1000 Death Hypovolemic 
shock
Ever Ever
61 Cip M 2, 09 ,50,000 Sr Well No data Death Intracranial  
hemorrhage
Ever Ever
62 Pcb F 5, 03 ,50,000 Sr Well ,1000 Cr Never Never
63 Pcb F 5, 07 $50,000 Hr Under ,1000 Cr Never Ever
64 Cip M 3, 04 ,50,000 Sr Well $1000 Cr Never Never
65 Cip M 8, 09 ,50,000 Sr Well ,1000 Cr Never Ever
66 Cip F 4, 08 ,50,000 Sr Under ,1000 Cr Never Never
67 Pcb F 2, 09 ,50,000 Sr Well ,1000 rD Ever Ever
68 Cip F 2, 07 ,50,000 Sr Well $1000 Death No data Never Ever
69 Pcb F 6, 09 ,50,000 Sr Under $1000 Cr Never Never
70 Cip M 10, 00 $50,000 Hr Well ,1000 Cr Never Never
71 Pcb M 8, 01 $50,000 Hr Under $1000 Abn Ever Ever
72 Cip M 3, 08 ,50,000 Sr Well $1000 Cr Ever Ever
73 Cip M 5, 09 ,50,000 Hr Under ,1000 Cr Never Ever
74 Cip M 4, 01 ,50,000 Sr Well No data Abn Never Never
75 Cip F 13, 00 ,50,000 Hr Well $1000 Death No data Never Never
76 Cip M 2, 03 $50,000 Hr Well $1000 rD Ever Ever
77 Pcb M 12, 01 ,50,000 Hr Well ,1000 Cr Never Never
78 Pcb M 8, 07 ,50,000 Sr Under ,1000 Cr Never Never
79 Cip F 4, 05 ,50,000 Sr Well ,1000 Cr Ever Never
80 Pcb M 2, 01 $50,000 Hr Well $1000 Cr Never Never
81 Pcb M 7, 05 $50,000 Hr Under $1000 Abn Never Ever
82 Pcb M 11, 01 ,50,000 Hr Under ,1000 Cr Never Never
83 Pcb M 14, 00 $50,000 Hr Well $1000 Cr Never Never
84 Cip M 10, 00 ,50,000 Hr Well ,1000 Death Varicella Never Never
85 Cip M 3, 08 ,50,000 Hr Well ,1000 Cr Never Never
86 Pcb M 12, 00 ,50,000 Hr Under ,1000 Cr Ever Ever
87 Cip F 2, 00 ,50,000 Sr Well ,1000 Cr Never Never
88 Cip M 5, 09 $50,000 Hr Well ,1000 Death Transfusion  
reaction
Never Never
89 Cip M 4, 04 ,50,000 Sr Well ,1000 Cr Never Never
90 Pcb M 14, 01 $50,000 Hr Under ,1000 Cr Ever Never
91 Pcb M 5, 05 ,50,000 Sr Well ,1000 Cr Never Never
92 Pcb M 2, 00 ,50,000 Sr Well ,1000 rD Never Never
93 Cip M 3, 00 ,50,000 Sr Well ,1000 Cr Ever Ever
94 Pcb F 5, 04 ,50,000 Sr Under ,1000 Abn Never Never
95 Cip M 3, 03 ,50,000 Sr Well ,1000 Cr Never Never
96 Pcb F 2, 02 ,50,000 Sr Well ,1000 Cr Never Never
97 Pcb M 1, 01 ,50,000 Hr Well ,1000 Cr Never Never
(Continued)
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Table 6 (Continued)
Patient Random Sex Age 
(years,  
months)
WBC  
count  
(/μl)
Risk  
group
Nutritional 
state
Day 8  
response 
(/μl)
Induction  
outcome
Cause  
of death
Fever Sepsis
98 Pcb F 8, 02 $50,000 Hr Under ,1000 Cr Never Ever
99 Cip F 6, 05 $50,000 Hr Well ,1000 Abn Never Never
100 Cip M 4, 09 $50,000 Hr Well ,1000 Death Intracranial  
hemorrhage
Never Ever
101 Pcb F 4, 00 $50,000 Hr Under ,1000 Cr Never Ever
102 Pcb F 3, 06 ,50,000 Sr Well ,1000 Cr Ever Ever
103 Cip M 3, 01 ,50,000 Hr Under $1000 Cr Never Never
104 Pcb F 14, 00 ,50,000 Hr Well ,1000 Cr Ever Never
105 Cip M 3, 11 ,50,000 Sr Well ,1000 Cr Never Ever
106 Pcb M 8, 04 ,50,000 Hr Well $1000 Cr Never Never
107 Pcb M 12, 01 ,50,000 Hr Under ,1000 Cr Never Never
108 Cip M 3, 06 ,50,000 Sr Under ,1000 Cr Ever Never
109 Cip F 5, 06 ,50,000 Sr Well ,1000 Cr Never Never
110 Cip F 5, 03 ,50,000 Sr Well ,1000 Cr Ever Ever
Abbreviations: Cip, ciprofloxacin; Pcb, placebo; F, female; M, male; SR, standard risk; HR, high risk; Well, well-nourished; Under, undernourished; CR, complete remission; 
rD, resistant disease; Abn, abandonment to treatment.
case: the arm A tablets indeed contained ciprofloxacin, and 
those of arm B were placebo. The finding of more toxic death 
in the ciprofloxacin arm in our study was contrary to most 
previous studies, which have shown reduced events of fever, 
sepsis, or mortality.6,9,27,28 We did not ascertain a definite cause 
for this finding.
Side effects related to ciprofloxacin in our study were 
mild and manageable, limited to nausea or vomiting and 
diarrhea as reported in previous studies.29,30 Neutropenia 
or marrow suppression caused by ciprofloxacin is rare.25 
When we checked our database, however, we found that the 
ciprofloxacin group had a lower nadir of absolute neutrophil 
count. This may explain the higher incidence of fever, sepsis 
and death. It may moreover influence the gut flora or gut 
mucosa in a negative way, facilitating pathogens to invade 
into the circulation. We thought that the lower nadir of neu-
trophil count in the ciprofloxacin group may have been a 
predisposing factor to fever and infection, sepsis, and death 
in this study. It is reasonable to assume that patients who got 
sepsis were at greater risk of death.
Another jeopardizing impact of ciprofloxacin and fluo-
roquinolone is the emergence of resistant bacteria after its 
administration as prophylactic antibiotic,31–36 but we could not 
find evidence for this because we were not able to conduct 
microbiological surveillance in this study. A further limita-
tion was the bitter taste of ciprofloxacin, which might have 
influenced compliance to take the tablets when the patients 
were at home. High induction death rate in our study was 
related to the setting in Dr Sardjito Hospital, where child-
hood ALL patients were nursed in a general pediatric ward, 
and lack of supportive care. Occasionally, unavailability of 
medicines and late initiation of intravenous antibiotic therapy 
in neutropenic patients with fever also contributed to our high 
death rate. Due to lack of microbiological data, we could not 
show the cause of the infective deaths.
Conclusion
The use of ciprofloxacin prophylaxis after chemotherapy 
in childhood ALL is not warranted in our setting. Further 
study is needed to determine the rational use of   ciprofloxacin 
in low-income countries and to limit the risk of the 
  occurrence of microbial resistance to this important class 
of antibiotics.
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